TNF and inflammatory bowel disease: The clinical disease activity grade and fecal calprotectin of IBD patients, a crucial indicator of intestinal inflammation, significantly decreased after 4 months of anti-TNF-α therapy (p = 0.004, p < 0.001, respectively).